Village-based Refill of ART After Same-day ART Start vs Clinic-based ART Refill for HIV-positive Individuals Not on ART During Home-based HIV Testing (Part B of GET ON Research Project)
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 257
- 试验地点
- 2
- 主要终点
- 12-months viral suppression
研究概览
简要总结
This cluster-randomized trial tests a differentiated care model for HIV-positive individuals not on ART during a home-based HIV testing campaign in rural Lesotho, Southern Africa. In intervention clusters, patients are offered a differentiated ART delivery package with two features. Firstly, drug-refill and follow-up are provided by village health workers (VHW), reducing clinic visits to twice a year for laboratory assessment. Secondly, participants have the option of receiving individually tailored adherence reminders and viral load result notifications via SMS.
详细描述
The VIBRA trial is a cluster randomized controlled, open-label, superiority trial in a resource-limited setting. The trial is linked to a another trial, the HOSENG (HOme-based SElf-testiNG) trial, that is described elsewhere (NCT03598686). Together, they consitute the GET ON (GETing tOwards Ninety) research project. The HOSENG study, with its home-based HIV testing campaign, provides the recruitment platform for the VIBRA study. The reasons for this interlinked design are: a) potential study participants for VIBRA trial (HIV-positive individuals not on ART) are to be recruited during a home-based HIV testing campaign and hence, it allows us to assess the entire HIV care cascade in one larger project, and b) both trials rely on interventions involving VHWs, who need to be randomized and specifically trained. Therefore, it is efficient and feasible to run both trials parallel and randomize at one time point only. The rational for a cluster randomized design is the reliance of the trial on the VHWs and, thus, the high risk of cross-contamination between the study arms if randomization would be done at individual level.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 10 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
12-months viral suppression
时间窗: 12 months (range: 10 - 15 months) after enrolment.
Viral suppression at 12 months, defined as the proportion of all participants with a VL \<20 copies/mL
12-months viral suppression (<400copies/mL)
时间窗: 12 months (range: 10 - 15 months) after enrolment.
Viral suppression at 12 months, defined as the proportion of all participants with a VL \<400 copies/mL
次要结局
- Sustained viral suppression(12 months (range 5 - 15 months) after enrollment)
- Loss to follow-up at 12 months(12 months (range 10 - 15 months) after enrollment)
- Confirmed transfer out at 12 months(12 months (range 10 - 15 months) after enrolment)
- Alternative viral suppression at 6 months(6 months (range 5 - 8 months) after enrolment)
- 3-months linkage to care(90 days)
- 12-months retention in care(12 months (range 10 - 15 months) after enrolment)
- All-cause mortality at 12 months(12 months (range 10 - 15 months) after enrolment)
- 1-month linkage to care(30 days after enrollment)
- 6-months viral suppression(6 months (range 5 - 8 months) after enrolment)
- Alternative viral suppression at 12 months(12 months (range 10 - 15 months) after enrolment.)
- 6-months retention in care(5-8 months after enrollment)
- Unconfirmed transfer out at 12 months(12 months (range 10 - 15 months) after enrolment)
研究者
Niklaus Labhardt
Principal Investigator
Swiss Tropical & Public Health Institute